Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

被引：36
|
作者：
Udwadia, Zarir F. [1 ]
Mullerpattan, Jai B. [1 ]
Balakrishnan, Canchi [2 ]
Richeldi, Luca [3 ]
机构：
[1] PD Hinduja Natl Hosp & Med Res Ctr, Dept Resp Med, Veer Savarkar Marg, Bombay 400016, Maharashtra, India
[2] PD Hinduja Natl Hosp & Med Res Ctr, Dept Rheumatol, Bombay, Maharashtra, India
[3] Univ Modena & Reggio Emilia, Dept Resp Med, Ctr Rare Lung Dis, Chair Interstitial Lung Dis, Modena, Italy
来源：
LUNG INDIA | 2015年 / 32卷 / 01期
关键词：
Interstitial lung disease; pirfenidone; systemic sclerosis;
D O I：
10.4103/0970-2113.148451
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Pirfenidone is an anti-fibrotic drug which has been approved for the management of patients with Idiopathic Pulmonary Fibrosis (IPF). However, its role in interstitial lung disease (ILD) due to other causes such as systemic sclerosis (SSc) is not clear. We present a case of a patient with SSc associated ILD who showed a subjective as well as objective improvement in lung function with pirfenidone.
引用
收藏
页码：50 / 52
页数：3
相关论文
共 50 条
  • [1] Improved Pulmonary Function And Lung Shadow With Pirfenidone Administration For A Chinese Case With Systemic Sclerosis Associated Interstitial Lung Disease
    Huang, H.
    Li, S.
    Xu, K.
    Bi, Y.
    Feng, R.
    Xu, Z.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [2] The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease
    Martin-Lopez, Maria
    Carreira, Patricia E.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (20)
  • [3] PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Cuomo, G.
    Di Vico, C.
    Perretta, D.
    Iandoli, C.
    Ciaburri, R.
    Adamo, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1657 - 1658
  • [4] IMPROVEMENT OF PULMONARY FUNCTION IN A PATIENT WITH INTERSTITIAL LUNG DISEASE SECONDARY TO SYSTEMIC SCLEROSIS AFTER TREATMENT WITH TOCILIZUMAB
    Severino, A.
    Vigone, B.
    Beretta, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S136 - S136
  • [5] Clinical Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-associated Interstitial Lung Disease
    Han, Kyung-Il
    Hwang, Jung Hwa
    Nam, Bo Da
    Song, Jin Woo
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [6] A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease A CARE-compliant article
    Huang, Hui
    Feng, Rui E.
    Li, Shan
    Xu, Kai
    Bi, Ye Lan
    Xu, Zuo Jun
    MEDICINE, 2016, 95 (27)
  • [7] Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis
    Phillips, Kristine
    Byrne-Dugan, Cathryn
    Batterson, Eric
    Seibold, James R.
    NATURE REVIEWS RHEUMATOLOGY, 2009, 5 (04) : 225 - 228
  • [8] Progress in progressive pulmonary fibrosis: biomarkers of systemic sclerosis-associated interstitial lung disease
    Takada, Toshinori
    RHEUMATOLOGY, 2024, 63 (11) : 2907 - 2908
  • [9] Rapidly progressive fatal interstitial lung disease in a patient with systemic sclerosis
    Kristine Phillips
    Cathryn Byrne-Dugan
    Eric Batterson
    James R. Seibold
    Nature Reviews Rheumatology, 2009, 5 : 225 - 228
  • [10] Lung Function And Survival In Systemic Sclerosis Associated Interstitial Lung Disease
    Shadly, S. M.
    Johnson, S. R.
    Chau, C.
    Marras, T. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
12345